 Xin Dang
Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| JC Virus | 23 | 2021 | 106 | 3.700 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 19 | 2021 | 121 | 3.300 |
Why?
| | Sequence Deletion | 4 | 2012 | 21 | 1.290 |
Why?
| | Capsid Proteins | 7 | 2019 | 29 | 1.110 |
Why?
| | Simian virus 40 | 4 | 2013 | 13 | 0.850 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2014 | 136 | 0.850 |
Why?
| | Polyomavirus Infections | 5 | 2018 | 29 | 0.850 |
Why?
| | Cerebellar Diseases | 2 | 2018 | 11 | 0.640 |
Why?
| | Neurons | 5 | 2019 | 407 | 0.630 |
Why?
| | Viral Regulatory and Accessory Proteins | 2 | 2013 | 15 | 0.600 |
Why?
| | Luminescent Proteins | 1 | 2015 | 11 | 0.590 |
Why?
| | Genes, Reporter | 1 | 2015 | 32 | 0.590 |
Why?
| | Viral Proteins | 1 | 2015 | 30 | 0.590 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 2 | 2014 | 12 | 0.550 |
Why?
| | Spinocerebellar Degenerations | 1 | 2013 | 4 | 0.520 |
Why?
| | Tumor Virus Infections | 2 | 2013 | 19 | 0.490 |
Why?
| | Genes, Viral | 3 | 2018 | 14 | 0.490 |
Why?
| | Multiple Sclerosis | 4 | 2014 | 91 | 0.450 |
Why?
| | DNA, Viral | 5 | 2019 | 107 | 0.440 |
Why?
| | Polyomavirus | 1 | 2011 | 6 | 0.440 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2021 | 225 | 0.440 |
Why?
| | Tuberculosis, Meningeal | 2 | 2021 | 5 | 0.420 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 2 | 2013 | 22 | 0.410 |
Why?
| | Amino Acid Sequence | 4 | 2012 | 254 | 0.370 |
Why?
| | Molecular Sequence Data | 4 | 2012 | 315 | 0.370 |
Why?
| | HIV Infections | 4 | 2021 | 951 | 0.340 |
Why?
| | Cell Line | 4 | 2021 | 360 | 0.330 |
Why?
| | Humans | 27 | 2021 | 31481 | 0.300 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2005 | 8 | 0.290 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2021 | 36 | 0.280 |
Why?
| | Macaca mulatta | 4 | 2013 | 70 | 0.260 |
Why?
| | Brain | 5 | 2018 | 1655 | 0.260 |
Why?
| | Neuroglia | 2 | 2021 | 48 | 0.250 |
Why?
| | Choroid Plexus | 2 | 2021 | 10 | 0.250 |
Why?
| | Genotype | 2 | 2021 | 423 | 0.240 |
Why?
| | Crotonates | 1 | 2021 | 4 | 0.230 |
Why?
| | Toluidines | 1 | 2021 | 4 | 0.230 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 9 | 0.230 |
Why?
| | DNA Viruses | 1 | 2021 | 7 | 0.230 |
Why?
| | Nitriles | 1 | 2021 | 17 | 0.230 |
Why?
| | Hydroxybutyrates | 1 | 2021 | 7 | 0.230 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.220 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 28 | 0.220 |
Why?
| | Astrocytes | 2 | 2021 | 135 | 0.220 |
Why?
| | Adult | 11 | 2021 | 9779 | 0.210 |
Why?
| | Antigens, Viral, Tumor | 3 | 2019 | 12 | 0.210 |
Why?
| | Mitochondria | 1 | 2021 | 91 | 0.210 |
Why?
| | Meninges | 2 | 2019 | 7 | 0.210 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2014 | 49 | 0.210 |
Why?
| | Pyramidal Cells | 2 | 2012 | 46 | 0.210 |
Why?
| | Simian immunodeficiency virus | 2 | 2013 | 22 | 0.200 |
Why?
| | Meningoencephalitis | 2 | 2013 | 10 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 179 | 0.200 |
Why?
| | Cells, Cultured | 4 | 2021 | 802 | 0.200 |
Why?
| | Capsid | 2 | 2014 | 12 | 0.200 |
Why?
| | Base Sequence | 2 | 2012 | 166 | 0.190 |
Why?
| | Henipavirus Infections | 1 | 2019 | 2 | 0.190 |
Why?
| | Virus Diseases | 2 | 2021 | 15 | 0.190 |
Why?
| | Female | 14 | 2021 | 18253 | 0.190 |
Why?
| | Pandemics | 1 | 2021 | 203 | 0.190 |
Why?
| | Immunocompromised Host | 3 | 2016 | 55 | 0.190 |
Why?
| | Oligodendroglia | 1 | 2019 | 34 | 0.190 |
Why?
| | Sequence Alignment | 2 | 2011 | 29 | 0.190 |
Why?
| | Immunologic Factors | 2 | 2021 | 53 | 0.190 |
Why?
| | Recombination, Genetic | 2 | 2015 | 15 | 0.180 |
Why?
| | Animals | 6 | 2013 | 5312 | 0.170 |
Why?
| | Coinfection | 2 | 2019 | 33 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 42 | 0.170 |
Why?
| | Male | 11 | 2021 | 17583 | 0.170 |
Why?
| | HIV-1 | 1 | 2021 | 446 | 0.170 |
Why?
| | Young Adult | 4 | 2021 | 2277 | 0.170 |
Why?
| | HIV | 3 | 2019 | 89 | 0.160 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2016 | 2 | 0.160 |
Why?
| | Malformations of Cortical Development, Group I | 1 | 2016 | 3 | 0.160 |
Why?
| | Lymphopenia | 1 | 2016 | 7 | 0.160 |
Why?
| | Interleukin-7 | 1 | 2016 | 25 | 0.160 |
Why?
| | Fibroblasts | 2 | 2008 | 98 | 0.160 |
Why?
| | Middle Aged | 8 | 2021 | 11209 | 0.150 |
Why?
| | Cerebellum | 2 | 2006 | 57 | 0.150 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2015 | 39 | 0.150 |
Why?
| | Ataxia | 1 | 2016 | 79 | 0.150 |
Why?
| | Virus Replication | 2 | 2013 | 96 | 0.140 |
Why?
| | Zambia | 3 | 2021 | 17 | 0.140 |
Why?
| | Meningitis, Aseptic | 1 | 2014 | 6 | 0.140 |
Why?
| | HIV Seronegativity | 1 | 2014 | 44 | 0.140 |
Why?
| | Herpesviridae | 1 | 2014 | 3 | 0.140 |
Why?
| | Hydrocephalus | 1 | 2014 | 31 | 0.140 |
Why?
| | Cerebellar Ataxia | 1 | 2014 | 7 | 0.140 |
Why?
| | Central Nervous System Infections | 1 | 2014 | 7 | 0.140 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2006 | 37 | 0.130 |
Why?
| | Virus Assembly | 1 | 2013 | 2 | 0.130 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 48 | 0.130 |
Why?
| | Virion | 1 | 2013 | 16 | 0.130 |
Why?
| | DNA | 1 | 2014 | 139 | 0.130 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2013 | 16 | 0.130 |
Why?
| | Leukoencephalopathies | 1 | 2013 | 9 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2015 | 139 | 0.130 |
Why?
| | Bacterial Infections | 1 | 2014 | 71 | 0.130 |
Why?
| | Demyelinating Diseases | 2 | 2021 | 13 | 0.130 |
Why?
| | Spinal Cord | 1 | 2013 | 99 | 0.120 |
Why?
| | Viral Tropism | 1 | 2012 | 3 | 0.120 |
Why?
| | Genes, Regulator | 1 | 2012 | 4 | 0.120 |
Why?
| | Tandem Repeat Sequences | 1 | 2012 | 5 | 0.120 |
Why?
| | Viral Core Proteins | 1 | 2012 | 6 | 0.120 |
Why?
| | Genome, Viral | 1 | 2012 | 14 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 73 | 0.120 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2021 | 151 | 0.110 |
Why?
| | Amino Acid Motifs | 1 | 2011 | 20 | 0.110 |
Why?
| | Immunocompetence | 1 | 2011 | 7 | 0.110 |
Why?
| | Adolescent | 2 | 2019 | 2667 | 0.100 |
Why?
| | Mass Screening | 1 | 2011 | 199 | 0.090 |
Why?
| | Gene Expression | 2 | 2021 | 272 | 0.090 |
Why?
| | Transfection | 1 | 2008 | 154 | 0.090 |
Why?
| | CD4 Lymphocyte Count | 2 | 2021 | 161 | 0.090 |
Why?
| | Cerebral Cortex | 1 | 2009 | 206 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2008 | 832 | 0.080 |
Why?
| | Aged | 6 | 2021 | 10295 | 0.080 |
Why?
| | Genetic Variation | 1 | 2006 | 113 | 0.080 |
Why?
| | Autopsy | 2 | 2019 | 340 | 0.070 |
Why?
| | Viral Load | 2 | 2021 | 213 | 0.070 |
Why?
| | Brain Diseases | 1 | 2005 | 90 | 0.070 |
Why?
| | Liver Transplantation | 1 | 2005 | 114 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2019 | 494 | 0.060 |
Why?
| | HLA-A2 Antigen | 1 | 2002 | 6 | 0.060 |
Why?
| | Immunodominant Epitopes | 1 | 2021 | 6 | 0.060 |
Why?
| | Stress, Physiological | 1 | 2021 | 26 | 0.060 |
Why?
| | Mitochondrial Proteins | 1 | 2021 | 46 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2021 | 101 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 332 | 0.050 |
Why?
| | Survival Rate | 1 | 2021 | 465 | 0.050 |
Why?
| | Transcription Factors | 1 | 2021 | 180 | 0.050 |
Why?
| | Prevalence | 1 | 2021 | 544 | 0.050 |
Why?
| | Cerebellar Cortex | 1 | 2019 | 8 | 0.050 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 6 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2019 | 22 | 0.050 |
Why?
| | Apoptosis | 1 | 2021 | 292 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 264 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2014 | 467 | 0.050 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 166 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 1273 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 687 | 0.040 |
Why?
| | Mefloquine | 1 | 2016 | 3 | 0.040 |
Why?
| | Mianserin | 1 | 2016 | 16 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2016 | 25 | 0.040 |
Why?
| | Methylprednisolone | 1 | 2016 | 26 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2016 | 295 | 0.040 |
Why?
| | Pancytopenia | 1 | 2014 | 4 | 0.030 |
Why?
| | Interferon-beta | 1 | 2014 | 8 | 0.030 |
Why?
| | Cytoplasmic Granules | 1 | 2014 | 14 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 2014 | 2 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2014 | 2 | 0.030 |
Why?
| | DNA, Fungal | 1 | 2014 | 4 | 0.030 |
Why?
| | Cryptococcus | 1 | 2014 | 3 | 0.030 |
Why?
| | Streptococcus pneumoniae | 1 | 2014 | 7 | 0.030 |
Why?
| | Cryptococcosis | 1 | 2014 | 6 | 0.030 |
Why?
| | Toxoplasmosis | 1 | 2014 | 11 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 75 | 0.030 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 17 | 0.030 |
Why?
| | Toxoplasma | 1 | 2014 | 19 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 12 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2014 | 54 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2014 | 124 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 3 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 148 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2014 | 120 | 0.030 |
Why?
| | COS Cells | 1 | 2013 | 51 | 0.030 |
Why?
| | Gene Deletion | 1 | 2013 | 57 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2013 | 28 | 0.030 |
Why?
| | Chronic Disease | 1 | 2016 | 544 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2013 | 125 | 0.030 |
Why?
| | Seizures | 1 | 2014 | 88 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2014 | 242 | 0.030 |
Why?
| | Phenotype | 1 | 2013 | 379 | 0.030 |
Why?
| | Mutation | 1 | 2014 | 464 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2014 | 150 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 986 | 0.030 |
Why?
| | Time Factors | 1 | 2014 | 1902 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2014 | 2028 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 2006 | 13 | 0.020 |
Why?
| | Myelin Sheath | 1 | 2006 | 23 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 1075 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2004 | 14 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2014 | 3591 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2004 | 41 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2014 | 3910 | 0.020 |
Why?
| | Radiography | 1 | 2005 | 717 | 0.010 |
Why?
| | Antigens, Viral | 1 | 2002 | 21 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2002 | 18 | 0.010 |
Why?
| | Survivors | 1 | 2002 | 68 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 217 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 278 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 1028 | 0.010 |
Why?
|
|
Dang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|